Gary K. Lee
Chief Scientific Officer · Lyell Immunopharma, Inc.
- 2025
- Aug 25, 2026
- 9
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Gary K. Lee files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ARCH Venture Partners IX, LLC - $12.50M in LYEL purchases and sales in the last 12 months
- ARCH Venture Fund XIII, L.P. - $12.50M in LYEL purchases and sales in the last 12 months
- Lynn Seely - $353K in LYEL purchases and sales in the last 12 months
- Stephen J. Hill - $51K in LYEL purchases and sales in the last 12 months
- David Shook - $31K in LYEL purchases and sales in the last 12 months
- Veronica Sanchez Bulis - $23K in LYEL purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Gary K. Lee?
Gary K. Lee is a corporate insider, tracked as Chief Scientific Officer of Lyell Immunopharma, Inc. (LYEL). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Gary K. Lee submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Gary K. Lee been buying or selling stock?
Recorded transactions: 0 open-market purchases and 9 open-market sales ($90K) across all tracked filings.
